Integration of Pharmaceutical Discovery and Development Case Histories /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Borchardt, Ronald T. (Επιμελητής έκδοσης), Freidinger, Roger M. (Επιμελητής έκδοσης), Sawyer, Tomi K. (Επιμελητής έκδοσης), Smith, Philip L. (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Boston, MA : Springer US, 1998.
• Σειρά: Pharmaceutical Biotechnology, 11
• Θέματα: Life sciences.; Biochemistry.; Animal physiology.; Life Sciences.; Animal Physiology.; Biochemistry, general.

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift oc...

Πίνακας περιεχομένων:

• Renin Inhibitors
• The Discovery and Development of Angiotensin II Antagonists
• Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor
• Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707
• Endothelin Receptor Antagonists
• LHRH Antagonists
• LHRH Agonists
• Discovery and Development of Somatostatin Agonists
• Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors
• The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development
• De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule
• Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate
• Famciclovir
• The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics
• Hematoregulators
• Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase
• Discovery of a Potent and Selective ?1A Antagonist
• Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2
• The Anxieties of Drug Discovery and Development
• CI-1015
• Orally Active Nonpeptide CCK-A Agonists
• Orally Active Growth Hormone Secretagogues
• Dorzolamide, a 40-Year Wait
• Discovery and Development of Novel Melanogenic Drugs.